Low endoglin vascular density and Ki67 index in Gleason score 6 tumours may identify prostate cancer patients suitable for surveillance

References

• Shariat SF, Karakiewicz PI, Roehrborn CG, Kattan MW. An updated catalog of prostate cancer predictive tools. Cancer 2008;113:3075–99.
   PubMed Web of Science ®Google Scholar
• Amin M, Boccon-Gibod L, Egevad L, Epstein JI, Humphrey PA, Mikuz G, Prognostic and predictive factors and reporting of prostate carcinoma in prostate needle biopsy specimens. Scand J Urol Nephrol Suppl 2005;216:20–33.
   PubMedGoogle Scholar
• Schroder FH, van der Cruijsen-Koeter I, de Koning HJ, Vis AN, Hoedemaeker RF, Kranse R. Prostate cancer detection at low prostate specific antigen. J Urol 2000;163:806–12.
   PubMed Web of Science ®Google Scholar
• Khatami A, Aus G, Damber JE, Lilja H, Lodding P, Hugosson J. PSA doubling time predicts the outcome after active surveillance in screening-detected prostate cancer: results from the European randomized study of screening for prostate cancer, Sweden section. Int J Cancer 2007;120:170–4.
   PubMed Web of Science ®Google Scholar
• Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010;102:950–8.
   PubMedGoogle Scholar
• Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010;28:126–31.
   PubMed Web of Science ®Google Scholar
• Mohler JL. The 2010 NCCN clinical practice guidelines in oncology on prostate cancer. J Natl Compr Canc Netw 2010;8:145.
   PubMed Web of Science ®Google Scholar
• van der Poel HG. Molecular markers in the diagnosis of prostate cancer. Crit Rev Oncol Hematol 2007;61:104–39.
   PubMed Web of Science ®Google Scholar
• Chung SC, Hammarsten P, Josefsson A, Stattin P, Granfors T, Egevad L, A high cannabinoid CB(1) receptor immunoreactivity is associated with disease severity and outcome in prostate cancer. Eur J Cancer 2009;45:174–82.
   PubMed Web of Science ®Google Scholar
• Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of the Gleason score in prostate cancer. BJU Int 2002;89:538–42.
   PubMed Web of Science ®Google Scholar
• Stattin P, Damber JE, Karlberg L, Bergh A. Cell proliferation assessed by Ki-67 immunoreactivity on formalin fixed tissues is a predictive factor for survival in prostate cancer. J Urol 1997;157:219–22.
   PubMed Web of Science ®Google Scholar
• Halin S, Hammarsten P, Adamo H, Wikstrom P, Bergh A. The tumor indicating normal tissue (TINT) that surrounds tumours can be used to diagnose and prognosticate prostate cancer. Future Med Diagn 2010; Accepted January 2011;5(1):37-47.
   Google Scholar
• Inoue T, Segawa T, Shiraishi T, Yoshida T, Toda Y, Yamada T, Androgen receptor, Ki67, and p53 expression in radical prostatectomy specimens predict treatment failure in Japanese population. Urology 2005;66:332–7.
   PubMed Web of Science ®Google Scholar
• Zellweger T, Ninck C, Mirlacher M, Annefeld M, Glass AG, Gasser TC, Tissue microarray analysis reveals prognostic significance of syndecan-1 expression in prostate cancer. Prostate 2003;55:20–9.
   PubMed Web of Science ®Google Scholar
• Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T. EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008;122:595–602.
   PubMed Web of Science ®Google Scholar
• Comperat E, Roupret M, Drouin SJ, Camparo P, Bitker MO, Houlgatte A, Tissue expression of IL16 in prostate cancer and its association with recurrence after radical prostatectomy. Prostate 2010;70:1622–7.
   PubMed Web of Science ®Google Scholar
• Pontes-Junior J, Reis ST, de Oliveira LC, Sant'anna AC, Dall'oglio MF, Antunes AA, Association between integrin expression and prognosis in localized prostate cancer. Prostate 2010;70:1189–95.
   PubMed Web of Science ®Google Scholar
• Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Delineation of prognostic biomarkers in prostate cancer. Nature 2001;412:822–6.
   PubMed Web of Science ®Google Scholar
• Domingo-Domenech J, Mellado B, Ferrer B, Truan D, Codony-Servat J, Sauleda S, Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer 2005;93:1285–94.
   PubMed Web of Science ®Google Scholar
• Li R, Wheeler T, Dai H, Frolov A, Thompson T, Ayala G. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy. Am J Surg Pathol 2004;28:928–34.
   PubMed Web of Science ®Google Scholar
• Dahlman A, Rexhepaj E, Brennan DJ, Gallagher WM, Gaber A, Lindgren A, Evaluation of the prognostic significance of MSMB and CRISP3 in prostate cancer using automated image analysis. Mod Pathol 2011;24:708–19.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Fisher G, Kattan MW, Berney D, Oliver T, Foster CS, Long-term outcome among men with conservatively treated localised prostate cancer. Br J Cancer 2006;95:1186–94.
   PubMed Web of Science ®Google Scholar
• Manley S, Mucci NR, De Marzo AM, Rubin MA. Relational database structure to manage high-density tissue microarray data and images for pathology studies focusing on clinical outcome: the prostate specialized program of research excellence model. Am J Pathol 2001;159:837–43.
   PubMed Web of Science ®Google Scholar
• Hansen RL, Heeboll S, Ottosen PD, Dyrskjot L, Borre M. Smarcc1 expression: a significant predictor of disease-specific survival in patients with clinically localized prostate cancer treated with no intention to cure. Scand J Urol Nephrol 2011;45:91–6.
   PubMed Web of Science ®Google Scholar
• Berney DM, Gopalan A, Kudahetti S, Fisher G, Ambroisine L, Foster CS, Ki-67 and outcome in clinically localised prostate cancer: analysis of conservatively treated prostate cancer patients from the Trans-Atlantic Prostate Group study. Br J Cancer 2009;100:888–93.
   PubMed Web of Science ®Google Scholar
• Kudahetti SC, Fisher G, Ambroisine L, Prowse D, Kattan MW, Foster CS, Immunohistochemistry for p16, but not Rb or p21, is an independent predictor of prognosis in conservatively treated, clinically localised prostate cancer. Pathology 2010;42:519–23.
   PubMed Web of Science ®Google Scholar
• Demichelis F, Fall K, Perner S, Andren O, Schmidt F, Setlur SR, TMPRSS2:ERG gene fusion associated with lethal prostate cancer in a watchful waiting cohort. Oncogene 2007;26:4596–9.
   PubMed Web of Science ®Google Scholar
• Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE, Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011;12:245–55.
   PubMed Web of Science ®Google Scholar
• Rubin MA, Bismar TA, Andren O, Mucci L, Kim R, Shen R, Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death. Cancer Epidemiol Biomarkers Prev 2005;14:1424–32.
   PubMed Web of Science ®Google Scholar
• Andren O, Fall K, Andersson SO, Rubin MA, Bismar TA, Karlsson M, MUC-1 gene is associated with prostate cancer death: a 20-year follow-up of a population-based study in Sweden. Br J Cancer 2007;97:730–4.
   PubMed Web of Science ®Google Scholar
• Mucci LA, Pawitan Y, Demichelis F, Fall K, Stark JR, Adami HO, Testing a multigene signature of prostate cancer death in the Swedish Watchful Waiting Cohort. Cancer Epidemiol Biomarkers Prev 2008l;17:1682–8.
   PubMed Web of Science ®Google Scholar
• Hammarsten P, Karalija A, Josefsson A, Rudolfsson SH, Wikstrom P, Egevad L, Low levels of phosphorylated epidermal growth factor receptor in nonmalignant and malignant prostate tissue predict favorable outcome in prostate cancer patients. Clin Cancer Res 2010;16:1245–55.
   PubMed Web of Science ®Google Scholar
• Johansson A, Rudolfsson S, Hammarsten P, Halin S, Pietras K, Jones J, Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol 2010;177:1031–41.
   PubMed Web of Science ®Google Scholar
• Datta MW, True LD, Nelson PS, Amin MB. The role of tissue microarrays in prostate cancer biomarker discovery. Adv Anat Pathol 2007;14:408–18.
   PubMed Web of Science ®Google Scholar
• Wikstrom P, Lissbrant IF, Stattin P, Egevad L, Bergh A. Endoglin (CD105) is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002;51:268–75.
   PubMed Web of Science ®Google Scholar
• Josefsson A, Wikstrom P, Granfors T, Egevad L, Karlberg L, Stattin P, Tumor size, vascular density and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors in patients with long follow-up and non-curative treatment. Eur Urol 2005;48:577–83.
   PubMed Web of Science ®Google Scholar
• El-Gohary YM, Silverman JF, Olson PR, Liu YL, Cohen JK, Miller R, Endoglin (CD105) and vascular endothelial growth factor as prognostic markers in prostatic adenocarcinoma. Am J Clin Pathol 2007;127:572–9.
   PubMed Web of Science ®Google Scholar
• Fujita K, Ewing CM, Chan DY, Mangold LA, Partin AW, Isaacs WB, Endoglin (CD105) as a urinary and serum marker of prostate cancer. Int J Cancer 2009;124:664–9.
   PubMed Web of Science ®Google Scholar
• Svatek RS, Karam JA, Roehrborn CG, Karakiewicz PI, Slawin KM, Shariat SF. Preoperative plasma endoglin levels predict biochemical progression after radical prostatectomy. Clin Cancer Res 2008;14:3362–6.
   PubMed Web of Science ®Google Scholar
• Zellweger T, Gunther S, Zlobec I, Savic S, Sauter G, Moch H, Tumour growth fraction measured by immunohistochemical staining of Ki67 is an independent prognostic factor in preoperative prostate biopsies with small-volume or low-grade prostate cancer. Int J Cancer 2009;124:2116–23.
   PubMed Web of Science ®Google Scholar
• Jhavar S, Bartlett J, Kovacs G, Corbishley C, Dearnaley D, Eeles R, Biopsy tissue microarray study of Ki-67 expression in untreated, localized prostate cancer managed by active surveillance. Prostate Cancer Prostatic Dis 2009;12:143–7.
   PubMed Web of Science ®Google Scholar
• Khatami A, Pihl CG, Norrby K, Hugosson J, Damber JE. Is tumor vascularity in prostate core biopsies a predictor of PSA recurrence after radical prostatectomy? Acta Oncol 2005;44:362–8.
   PubMed Web of Science ®Google Scholar
• Halin S, Rudolfsson SH, Van Rooijen N, Bergh A. Extratumoral macrophages promote tumor and vascular growth in an orthotopic rat prostate tumor model. Neoplasia 2009;11:177–86.
   PubMed Web of Science ®Google Scholar
• Hagglof C, Hammarsten P, Josefsson A, Stattin P, Paulsson J, Bergh A, Stromal PDGFRbeta expression in prostate tumors and non-malignant prostate tissue predicts prostate cancer survival. PLoS ONE 2010;5:e10747.
   PubMed Web of Science ®Google Scholar
• Josefsson A, Adamo H, Hammarsten P, Granfors T, Stattin P, Egevad L, Prostate cancer increases hyaluronan in surrounding non-malignant stroma and this response is associated with tumor growth and an unfavorable outcome. Am J Pathol 2011;179:1961–8.
   PubMed Web of Science ®Google Scholar
• Wikstrom P, Marusic J, Stattin P, Bergh A. Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 2009;69:799–809.
   PubMed Web of Science ®Google Scholar